1.35
-0.02(-1.46%)
Currency In USD
| Previous Close | 1.37 |
| Open | 1.37 |
| Day High | 1.39 |
| Day Low | 1.34 |
| 52-Week High | 81.77 |
| 52-Week Low | 1.1 |
| Volume | 75,424 |
| Average Volume | 489,857 |
| Market Cap | 3.17M |
| PE | 0.03 |
| EPS | 40.66 |
| Moving Average 50 Days | 2.3 |
| Moving Average 200 Days | 8.36 |
| Change | -0.02 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0 as of June 01, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 3 years ago, it would be worth $0.05 as of June 01, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
GlobeNewswire Inc.
May 22, 2025 12:00 PM GMT
Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GlobeNewswire Inc.
May 16, 2025 1:15 PM GMT
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire Inc.
May 15, 2025 12:35 PM GMT
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis